Journals / Kocaeli Tıp Dergisi / 2018 / Cilt: 7 - Sayı: 1

A New Terrm in Oncology: Immunoconjugates

Onkolojide Yeni Bir Dönem: İmmunokonjugatlar

Pages
25–31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article, we aimed to summarize why immunoconjugates may be promising in cancer treatment, their structure and mechanism of action.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Chemotherapy agents work classically via cell cycle arrest, inhibition of cell replication or induction of apoptosis.
📊
Key Findings & Data:Unselectivity of these drugs at cell level limits their dose, where exceeding causes lethal toxicities, prevents dose increase even if it increases drug’s effect.
💡
Conclusion & Impact:In this article, we aimed to summarize why immunoconjugates may be promising in cancer treatment, their structure and mechanism of action.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Chemotherapy agents work classically via cell cycle arrest, inhibition of cell replication or induction of apoptosis. Unselectivity of these drugs at cell level limits their dose, where exceeding causes lethal toxicities, prevents dose increase even if it increases drug’s effect. This limited efficacy and high toxicity profile of chemotherapy drugs necessitate the search for new drugs. One of these new agents, immunoconjugates are molecules that combinean antibody against a specific antigen of cancer cell and a cytotoxic agent (cytotoxic drug, radioisotope, toxin) with a strong chemical bond. This bond ensures antibody and cytotoxic agent do not split before the drug reaches to the cancer cell, the cytotoxic agent is carried into the cell, that makes immunoconjugates cancer cell specific drugs. In this article, we aimed to summarize why immunoconjugates may be promising in cancer treatment, their structure and mechanism of action.

Özet

Klasik kemoterapötik ilaçlar hücre siklusunda arrest, hücre replikasyonunun durdurulması ve apopitoz indüksiyonu ile etki gösterir. Ancak bu ilaçların kanser hücresine spesifik olmaması nedeniyle belirli dozlar üzerinde kullanımı ölümcül toksisitelere neden olabilir. Bu nedenle ilacın etkinliği doz bağımlı olsa da, toksisite nedeniyle doz belirli bir seviyede sınırlanır. Yüksek yan etki nedeniyle sınırlanmış etkinlik, tedavide yeni moleküller geliştirilmesine neden olmuştur. Bu yeni geliştirilen ilaçlardan, immunokonjugatlar kanser hücresinin bir antijenine karşı geliştirilmiş antikor ve hücreye toksik olan bir ajanın (sitotoksik ilaç, radyoizotop, toksin) güçlü bir bağ ile birleştirilmesiyle oluşturulur. Bu bağ, antikor ve ajanın hücreye ulaşmadan ayrılmamasını ve ajanın hücre içine ulaşmasını sağlar. Bu mekanizma, immunokonjugatların kanser hücresine spesifik olmasını sağlar. Bu makalede, geleceğin popüler tedavisi olabilecek immunokonjugatların özelliklerini ve neden daha etkin olduklarını özetlemeyi amaçladık.

🔖

Cite This Article

KAYA, M. N., CANER, B., AVCI, N. (2018). A New Terrm in Oncology: Immunoconjugates. Kocaeli Tıp Dergisi, Cilt: 7 - Sayı: 1, 25–31. https://ajindex.com/articles/205566

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Anish Thomas, Beverly A Teicher. Antibody–drug conjugates for cancer therapy. Lancet Oncol 2016; 17: e254–62
  2. Yokota T, et al. Micro autoradiographic analysis of the normal organ distribution of radio iodin at single-chain Fv and other immunoglobulin forms. Cancer Res 1993; 53: 3776–83
  3. Ward ES, Zhou J, Ghetie V, et al. Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. Int Immunol 2003; 15: 187–95
  4. Covell DG, et al. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab') 2 and Fab' in mice. Cancer Res 1986; 46: 3969–78
  5. Adams GP, et al. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 1998; 77: 1405–12
  6. Wu AM. Engineered antibodies for molecular imaging of cancer. Methods. 2014; 65: 139–47
  7. Olafsen T, Sirk SJ, Olma S, et al. ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same day imaging. Tumour Biol 2012; 33: 669–77
  8. Colcher D, et al. Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q J Nucl Med 1998; 42: 225–41
  9. Daver N, Kantarjian H, Ravandi F, et al. A phase II study of decitabine and gemtuzumabozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia 2016; 30: 268–73
  10. Sanderson RJ. Invivo drug-linker stability of an anti-CD30 dipeptide-like dauristatin immunoconjugate. Clin Cancer Res 2005; 11: 843– 52
  11. Pasquetto MV, et al. Targeted drug delivery using immunoconjugates: Principles and applications. J Immunother 2011; 34: 611–28
  12. Koblinski JE, Ahran M, Sloane BF. Unraveling the role of proteases in cancer. Clin Chim Acta 2000; 291: 113–35
  13. Sjogren HO, et al. Human carcinomas in athymic mice and rat sands genetic at carcinomas in immunocompetant rates. Cancer Res 1997; 57: 4530–36
  14. Saleh MN, et al. Phase I trial of the antilewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J Clin Oncol 2000; 18: 2282–92
  15. Dosio F, Brusa P, Cattel L. Immunotoxins and anti cancer drug conjugate assemblies: the role of the link age between components. 2011; 3: 848– 83
  16. Sutherland MS, et al. Lysosomal trafficking and cysteine protease metabolism confer targetspecific cytotoxicity by peptide-linked anti-CD30- auristatin conjugates. J Biol Chem 2006; 281: 10540–47
  17. Fuchs CS, et al. Randomized, controlled trial of irinotecan plus infusional, bolus